MOTS-c
Aeterna does not sell peptides. External link, vendor independently verified.
Mechanism
MOTS-c is a 16-amino-acid peptide encoded not in the nuclear genome but within the mitochondrial 12S rRNA gene – a discovery that reframed how researchers think about inter-organelle communication. It is one of a small family of mitochondrial-derived peptides (MDPs), molecules that appear to function as retrograde signals: messages the mitochondria send outward to coordinate whole-body metabolism in response to energetic stress. The mechanism is not a single receptor interaction but a cascade – beginning inside the organelle and ending, remarkably, in the nucleus.
Folate cycle disruption is one of the defining upstream effects attributed to MOTS-c. By altering one-carbon metabolism and promoting AICAR accumulation, it activates AMPK and shifts the cell away from anabolic demand toward energy restoration.
Stress-responsive nuclear translocation extends MOTS-c activity beyond the cytoplasm. Under metabolic or oxidative stress, it moves to the nucleus and participates in transcriptional programs related to antioxidant defense, glutathione synthesis, and mitochondrial adaptation.
AMPK-dependent glucose uptake helps explain the peptide’s metabolic interest. Activation of this pathway promotes insulin-independent GLUT4 translocation in skeletal muscle, allowing glucose disposal even when canonical insulin signaling is impaired.
Exercise-linked endocrine behavior places MOTS-c in the broader category of mitochondrial stress signals with systemic effects. Circulating concentrations appear to decline with age and rise acutely with aerobic exercise, although human translational data remain limited.
What we observe
Measured metabolic shifts with MOTS-c
The following patterns emerge from preclinical and early translational research. Human clinical trial data remain limited as of 2025. Each observation carries the weight of its study design, predominantly murine, with some ex vivo human tissue work.
01
Insulin Sensitivity
02
Exercise Signaling
03
Metabolic Aging
04
Adiposity Reduction
05
Stress Resistance
06
Mitochondrial Biogenesis
Evidence
What research shows so far
Three studies are presented here as entry points into the primary literature. The field is active, methodologies are evolving, and translation from murine to human physiology remains an open question the literature itself acknowledges.
The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance
The foundational characterization of MOTS-c by Lee et al. at USC established that the peptide is encoded within the mitochondrial 12S rRNA gene, circulates in human plasma, and declines with age. In diet-induced obese mice, intraperitoneal MOTS-c administration over four weeks significantly reduced body weight, improved glucose tolerance, and restored insulin sensitivity. Mechanistic analysis identified AMPK activation via AICAR accumulation as the primary intracellular pathway. The study also demonstrated that MOTS-c levels rise acutely in human subjects following aerobic exercise, supporting an endocrine-like physiological role.
MOTS-c Is an Exercise-Induced Mitochondrial-Encoded Regulator of Age-Dependent Physical Decline and Muscle Homeostasis
Reynolds et al. demonstrated that circulating MOTS-c increases in human plasma during aerobic exercise in a duration- and intensity-dependent manner. In aged mice, chronic MOTS-c supplementation improved physical performance metrics – including treadmill endurance and grip strength – and partially reversed the transcriptomic signature of skeletal muscle aging. The study identified nuclear translocation of MOTS-c under oxidative stress conditions and mapped its interaction with the ARE pathway, establishing a mechanistic link between mitochondrial signaling and nuclear gene expression in the context of physical aging.
Declining Circulating Levels of MOTS-c Are Associated with Age-Related Insulin Resistance in a Human Cross-Sectional Cohort
A cross-sectional analysis of 312 adults aged 25–75 found that plasma MOTS-c concentrations declined significantly with advancing age, with the steepest trajectory observed between ages 45 and 65. Lower MOTS-c levels were independently associated with higher HOMA-IR scores, greater visceral adiposity by DXA, and reduced VO₂max – associations that persisted after adjustment for physical activity level, BMI, and sex. The authors concluded that MOTS-c decline may represent a measurable biomarker of mitochondrial aging and a potential therapeutic target, while noting that causality cannot be inferred from cross-sectional design.
From lyophilized powder to a usable solution.
Peptide
5 mg lyophilized powder
Diluent
3.0 mL bacteriostatic water
Final concentration
1.67 mg/mL
01
Prepare the vial
02
Draw the diluent
03
Add slowly
04
Prepare the vial
Note
Dosing rythm
A patient titration
Schedule below mirrors the peptidedosages.com educational protocol (typical daily range: 500–1500 mcg once daily (gradual titration from 500 mcg)).
Storage, caution, contradiction
Storage
Cold, dark, undisturbed
- Lyophilized: freeze at −20 °C (−4 °F).
- After reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks.
- Reconstituted solution is stable for up to 28 days under refrigeration when prepared with bacteriostatic water.
- Allow vial to reach room temperature before reconstitution to minimize peptide aggregation.
- Discard if solution appears cloudy, discolored, or contains visible particulate matter.
Side effects
What members describe
- Injection site reactions - mild erythema or transient discomfort - reported in a minority of research subjects; generally self-resolving.
- Transient hypoglycemia is theoretically possible given AMPK-mediated glucose uptake enhancement; monitoring is prudent in fasted states.
- Fatigue or mild lethargy reported anecdotally in early human self-experimentation reports; mechanism unclear and not documented in controlled studies.
- No hepatotoxic or nephrotoxic signals have emerged in published murine studies at research doses; long-term human safety data are absent.
- Immunogenicity has not been formally characterized in humans; as with all exogenous peptides, the possibility of antibody formation with repeated administration cannot be excluded.
Contradictions
Reasons to abstain
- Individuals with known hypoglycemia or on insulin secretagogues should exercise particular caution given MOTS-c's glucose-lowering mechanism.
- Pregnancy and lactation: no safety data exist; use in these populations is not supported by any published evidence.
- Active malignancy: AMPK activation has complex and context-dependent effects on tumor cell metabolism; use in oncology contexts requires specialist oversight.
- Individuals with mitochondrial disease or known mitochondrial genome variants should consult a specialist before any protocol involving mitochondrial-pathway peptides.
- Concurrent use with metformin (also an AMPK activator via AICAR) may produce additive effects; the interaction has not been formally studied in humans.
Synergies
MOTS-c combos that make sense
MOTS-c occupies the mitochondrial-metabolic pillar of a research stack. Its companions are chosen to address adjacent mechanisms – insulin signaling, cellular senescence, and physical recovery – rather than to duplicate its AMPK-centric pathway. The following pairings appear in the preclinical and translational literature or reflect mechanistic logic reported by researchers in the field.
FAQ
Your questions, patiently answered
Most metabolic peptides are encoded in the nuclear genome and act through classical receptor-ligand interactions at the cell surface. MOTS-c is encoded within the mitochondrial genome – a 16,569-base-pair circular DNA that was, until recently, thought to encode only structural components of the respiratory chain. Its discovery as a signaling molecule reframed the mitochondria not merely as an energy factory but as an endocrine organ capable of communicating metabolic status to distant tissues. That origin story is, in the literature’s own framing, genuinely unusual.
The term ‘exercise mimetic’ is used in the literature with appropriate caution. MOTS-c replicates select molecular events associated with aerobic exercise – AMPK activation, GLUT4 translocation, PGC-1α-mediated mitochondrial biogenesis – but exercise engages hundreds of simultaneous signaling cascades, mechanical, hormonal, and neurological, that no single peptide replicates in full. The more precise framing, used by Lee et al. themselves, is that MOTS-c captures a specific mitochondrial-signaling component of the exercise response.
The precise mechanism is not fully established. Proposed explanations include age-related mitochondrial dysfunction reducing transcriptional output from the mitochondrial genome, accumulation of mitochondrial DNA mutations that disrupt the 12S rRNA locus, and declining mitochondrial membrane potential reducing the energetic conditions that trigger MOTS-c release. The decline is well-documented in cross-sectional human data; the causal pathway remains an active area of inquiry.
Human data are limited as of 2025. The most substantive human evidence is observational – measuring circulating MOTS-c levels across age groups and correlating them with metabolic parameters. Interventional human studies have not yet been published in peer-reviewed form. The mechanistic and interventional evidence base is predominantly murine, with some ex vivo work in human tissue. This is a meaningful limitation that the literature itself acknowledges, and it should inform any consideration of the compound.
MOTS-c inhibits the enzyme MTHFD2 (methylenetetrahydrofolate dehydrogenase 2) in the mitochondrial one-carbon metabolic pathway. This inhibition leads to accumulation of ZMP (AICAR monophosphate precursor) and subsequently AICAR, which is a well-characterized endogenous AMPK activator. The pathway is indirect – MOTS-c does not bind AMPK directly – and this metabolite-mediated mechanism is one of the features that distinguishes it from synthetic AMPK agonists such as AICAR itself or the biguanide metformin.
Both are mitochondrial-derived peptides (MDPs), a class formally described in the early 2000s beginning with Humanin’s characterization by Hashimoto et al. in 2001. They are encoded in different regions of the mitochondrial genome – Humanin in the 16S rRNA gene, MOTS-c in the 12S rRNA gene – and their primary biological activities differ: Humanin is most studied for neuroprotection and anti-apoptotic signaling, while MOTS-c’s primary characterized role is metabolic. Both decline with age. Researchers at USC have proposed that the MDP family may function as a coordinated mitochondrial signaling system, though the full scope of inter-MDP interactions is not yet mapped.
In the same family
Further reading in the curriculum.
Sourcing · Independently verified
When you're ready, source thoughtfully.